Vicente Valentí (V Valentí, Vicente Valenti)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

Radiation Therapy

Top Venues

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Cancer investigation

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Vicente Valentí, Laia Capdevila, Isabel Ruiz, Francisco Javier Ramos Pascual, Joan Badia, Susana Blázquez, Óscar Villuendas, Cristina Pérez, Laura Fernández-Sender, Mónica Córdoba, Carlos Alonso-Villaverde
Variation of Plasma Damage-Associated Molecular Patterns in Patients with Advanced Solid Tumors After Standard of Care Systemic Treatment. Cancer investigation (2023)
Vicente Valentí, Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Ramón Salazar
Olaratumab-induced Biomarker Modulation in Sarcomas-Letter. Molecular cancer therapeutics 20 (10) (2022)
Vicente Valentí, Paula Jiménez-Fonseca, Pavlos Msaouel, Ramón Salazar, Alberto Carmona-Bayonas
Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit. Cancer investigation 40 (2) (2021)
A Lozano, J Marruecos, J Rubió, N Farré, J Gómez-Millán, R Morera, I Planas, M Lanzuela, M G Vázquez-Masedo, L Cascallar, J Giralt, G Escames, Vicente Valentí, P Grima, R Bosser, C Tarragó, R Mesía
Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 23 (9) (2021)
Vicente Valentí, J Ramos, C Pérez, L Capdevila, I Ruiz, L Tikhomirova, M Sánchez, I Juez, M Llobera, E Sopena, J Rubió, R Salazar
Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 22 (6) (2019)